PWPS
FDMT icon

Pinnacle Wealth Planning Services’s 4D Molecular Therapeutics FDMT Stock Holding History

Pinnacle Wealth Planning Services’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$931 Hold
100
– – ﹤0.01% 2565
2025
Q4 		$750 Buy
+100
New +$1.01K ﹤0.01% 2614

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Pinnacle Wealth Planning Services's FDMT Position: Q1 2026 in Review

Pinnacle Wealth Planning Services held its 4D Molecular Therapeutics (FDMT) position steady in Q1 2026 at 100 shares worth $931. The position accounts for ﹤0.01% of the portfolio, ranked #2565.

Pinnacle Wealth Planning Services first reported a position in FDMT in Q4 2025 and has held it in 2 quarters since. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Pinnacle Wealth Planning Services held 100 shares of 4D Molecular Therapeutics worth $931 as of Q1 2026.
  • Pinnacle Wealth Planning Services left its 4D Molecular Therapeutics share count unchanged in Q1 2026.
  • 4D Molecular Therapeutics made up ﹤0.01% of Pinnacle Wealth Planning Services's portfolio in Q1 2026, its #2565 holding.
  • Pinnacle Wealth Planning Services first reported a position in 4D Molecular Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Pinnacle Wealth Planning Services's 13F filing for Q1 2026, filed 11 May 2026.